Australia: Antitrust authority approves new regulations to increase pharma transparency
The Australian Competition and Consumer Commission has given Australia’s pharmaceutical companies a timeline of two years to improve transparency in regards to the companies’ payments and sponsorships to healthcare professionals. While originally sought for a five year acceptance, Medicines Australia’s most recent Code of Conduct has been approved for two years; the new regulations are aimed at ensuring the makers of prescription drugs disclose the doctors and consumer groups they pay.
Featured News
Newsom Signs Sweeping California Data Center Oversight Package
Sep 21, 2026 by
CPI
Frozen-Potato Producers Must Face Most Price-Fixing Claims, Judge Rules
Sep 21, 2026 by
CPI
Paramount Reaches Deal With States, Clearing Major Hurdle to Warner Bros. Takeover
Sep 21, 2026 by
CPI
Russia Opens Antitrust Cases Over Generic Versions of Pfizer’s Eliquis
Sep 21, 2026 by
CPI
Google Faces €403 Million EU Privacy Penalty Over Location Tracking
Sep 21, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – National Security
Sep 22, 2026 by
CPI
National Security in U.S. Antitrust Enforcement: Toward a More Disciplined Framework
Sep 22, 2026 by
Rod Rosenstein & Timothy Finley
The Department of War’s M&A Review Guidance: What Companies in the Defense Industry Need to Know
Sep 22, 2026 by
Eric Stocking & Paul Ney
National Security, Resilience and the Boundaries of Merger Control
Sep 22, 2026 by
Beatriz Marques
National Security and Competition: Building Resilient Telecommunications Networks
Sep 22, 2026 by
Roslyn Layton